Exchange: NASDAQ·Updated 07:30 PM EST

FEMY News

News
all
press releases
Femasys Secures FDA Pathway for Non-Surgical Contraceptive
FDA clears modular PMA pathway for Femasys' FemBloc, an investigational non-surgical permanent birth control device for women in the US.read more...
Benzinga
Femasys Secures FDA Pathway for Non-Surgical Contraceptive
FDA clears modular PMA pathway for Femasys' FemBloc, an investigational non-surgical permanent birth control device for women in the US.read more...
Benzinga
More News
The U.S. Food and Drug Administration accepted Femasys’ modular premarket approval application for FemBloc, an experimental non-surgical permanent birth control technology.
Stocktwits
Wall Street Zen upgraded shares of Femasys from a "sell" rating to a "hold" rating in a research note on Friday...
MarketBeat
PharmaCyte noted that it now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash.
Stocktwits
Femasys secured FDA approval to proceed with the final phase of its pivotal FemBloc trial, a key step toward U.S. market approval for its non-surgical permanent birth control device.
Stocktwits
Femasys (FEMY) delivered earnings and revenue surprises of +11.11% and -48.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2,266.67% and -99.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -11.11% and -84.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
The offer price of $0.85 represents a discount of about 17% from the stock’s closing price on Thursday.
Stocktwits

Advertisement|Remove ads.